Adult medulloblastoma is defined in the MONDO ontology as a medulloblastoma arising from the brain, occurring in adults. Synonyms listed in the packet are medulloblastoma, adult brain medulloblastoma, and medulloblastoma of adults. The packet does not certify OMIM, Orphanet, or GARD identifiers, a prevalence estimate, or a curated clinical description for this entry. Those details are unknown in this packet and are not described here.

No phenotype annotations, age-of-onset categories, or GeneReviews clinical description are certified in this packet, and the total phenotype count is 0. Clinical features of adult medulloblastoma are therefore not described here. This reflects the limits of the packet and not an absence of documented features.

The packet lists no known genes and no inheritance patterns for this disease. The cause, including any genetic contribution, is not certified in this packet and is not described here.

No diagnostic methods, GeneReviews diagnosis content, or newborn screening information are certified in this packet. How adult medulloblastoma is diagnosed is therefore not described here.

The packet contains no FDA-approved treatments, orphan-drug records, foundational therapies, or GeneReviews management content for this disease. Treatment information is unknown in this packet, which does not imply that no treatments exist. Patient assistance programs may exist for some therapies; none are certified in this packet.

Natural history and prognosis are not certified in this packet, so no statement about disease course or outcomes is made here.

The packet reports 76 ClinicalTrials.gov records for the search term adult medulloblastoma, all counted as active. Several listed records enroll children and young adults or cover multiple tumor types, so their relevance to the adult entity is not established in the packet. Examples include NCT07087002, a Phase 1 GPC2-CAR T cell study for relapsed or refractory medulloblastoma in children and young adults sponsored by Stanford University (recruiting; 2025-08-28 to 2027-08-01); NCT07346157, a Phase 1 study of liothyronine with the BIT regimen sponsored by Sabine Mueller, MD, PhD (recruiting; 2026-08-21 to 2031-03-31); NCT07492316, a Phase 1 RNA-lipid particle vaccine study for recurrent or progressive medulloblastoma sponsored by the University of Florida (active, not recruiting; 2026-04-24 to 2031-03-31); and NCT06804655, a Phase 2 study of pharmacoscopy in refractory primary brain tumors sponsored by the University of Zurich (recruiting; 2026-09-11 to 2028-09-15). The packet's publication digest classifies 249 papers, with basic science and preclinical work the dominant type, 62 reviews, and 16 case reports. Trial statuses are as recorded in the packet and may have changed.